SPA
RNAM

Sherbrooke Park Advisers’s Avidity Biosciences RNAM Stock Holding History

Sherbrooke Park Advisers’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,769
Closed -$107K – 645
2023
Q3 		$107K Buy
+16,769
New +$144K 0.03% 449

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Sherbrooke Park Advisers's RNAM Position: Q4 2023 in Review

Sherbrooke Park Advisers sold out of Avidity Biosciences (RNAM) in Q4 2023, closing a stake of 16,769 shares — an estimated $107K sold.

Sherbrooke Park Advisers first reported a position in RNAM in Q3 2023 and held it in 1 quarter. The position peaked at $107K in Q3 2023. 144 funds tracked by Wall St. Rank hold RNAM as of Q4 2023.

  • Sherbrooke Park Advisers reported no remaining Avidity Biosciences position as of Q4 2023 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 16,769 Avidity Biosciences shares in Q4 2023, an estimated $107K.
  • Sherbrooke Park Advisers first reported a position in Avidity Biosciences in Q3 2023 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Avidity Biosciences position peaked at $107K in Q3 2023.
  • 144 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2023.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.